Literature DB >> 19077111

Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments.

B H Chong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19077111     DOI： 10.1111/j.1538-7836.2008.03258.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection.

Authors:  I Papakonstantinou; I Poulakidas
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

2.  Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes.

Authors:  Mengyi Zhang; Binhan Guo
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

3.  Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study.

Authors:  Adam Rosenberg; Catelyn Cashion; Fariya Ali; Harini Haran; Raaj K Biswas; Vivien Chen; Helen Crowther; Jennifer Curnow; Elyssa Deakin; Chee-Wee Tan; Yi Ling Tan; Andrew Vanlint; Christopher M Ward; Robert Bird; David J Rabbolini
Journal:  Res Pract Thromb Haemost       Date:  2022-09-18

4.  Isoniazid-induced Immune Thrombocytopenia.

Authors:  Gaku Kuwabara; Kumiyo Tazoe; Waki Imoto; Kazushi Yamairi; Wataru Shibata; Kazuhiro Oshima; Koichi Yamada; Yasuhiro Takagi; Satoshi Shiraishi; Masayuki Hino; Tomoya Kawaguchi; Hiroshi Kakeya
Journal:  Intern Med       Date:  2021-05-29       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.